Phase I study of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies

Trial Profile

Phase I study of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2008 Actual patient number changed from 71 to 59, as reported by Clinicaltrials.gov.
    • 05 Aug 2008 Actual patient number added from ClinicalTrials.gov.
    • 05 Aug 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top